Want to join the conversation?
$DPLO said it is now filling prescriptions for VENCLEXTA (venetoclax). The drug was recently approved by the U.S. Food and Drug Administration for the treatment of people with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, including those with 17p deletion.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.
$VZ down more than 2% after a disappointing third quarter. A lot of uncertainty on the Yahoo deal too.